Feature

Motion solution requirements for biologic delivery devices

From cancer to rheumatoid arthritis, biopharmaceuticals have revolutionised treatments, in some cases providing hope for patients who previously had no further options. Integral to their success are the delivery devices, which are driven by accurate, reliable motion systems.

31/08/2022 15:40:02

Font size:

Whether intended for disposable use or long-term administration, a tailored motion system will help the OEM best meet patient needs. Here, Portescap’s Jigar Fulia and Kanti Vala consider the
selection criteria for biologics system motion solutions.

Commonly known as biologics, these drugs are manufactured in or from a biological source, unlike typical medication which is developed through chemical synthesis.
The advantage is that biologics change the way the human immune system reacts, down-regulating the inflammatory response or supporting tumour-specific defence.

Biologics are delivered by injection and as they
have a much higher molecular weight than traditional, small-molecule chemical drugs, they are far more viscous. This makes accuracy in injecting the drugs increasingly critical. The drugs are typically administered
at regular intervals over a set time frame. Reliance for this task is placed on the delivery mechanism, which is driven by a miniaturised motion solution.

Read the full article in DPA's September issue

Written By Sophia Bell

Sophia Bell is the Group Editor of DPA, Connectivity, and PBSI. She joined the team in 2020 as Assistant Editor after achieving a First-Class Honours BA in English Literature and Film Studies from the University of East Anglia. In her current role, she leads the editorial strategy, driving digital growth and ensuring each title continues to deliver trusted, relevant insight for engineering and manufacturing professionals.